---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product comparison"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product comparison. Topics: Absence of head-to-head trials: company statement on cross-study comparisons, Absence of head-to-head trials of omalizumab and dupilumab, Barzolvolimab: phase 3 dosing regimens and planned BLA submission, Barzolvolimab: subcutaneous pre-filled syringe and potential self-administration at home, and 18 further topics. 22 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/product-comparison"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Absence of head-to-head trials: company statement on cross-study comparisons

> “Across reported studies, not based on head-to-head comparisons.”
> “Cross study comparisons are limited given differences in the design of the included trials, such as variations in statistical methods, patient populations, and dosing schedules, among other factors.”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-2.1.2.14-2"></a>

### Absence of head-to-head trials of omalizumab and dupilumab

> “However, the lack of head-to-head randomized trials makes it challenging to compare treatment outcomes between omalizumab and dupilumab.”

Source: [Mosnaim et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12990347/)

<a id="topic-2.1.2.14-3"></a>

### Barzolvolimab: phase 3 dosing regimens and planned BLA submission

> “1,939 patients were randomized (n=963 EMBARQ-CSU1; n=976 EMBARQ-CSU2) evenly to barzolvolimab 150 mg every 4 weeks (following 300 mg loading dose), barzolvolimab 300 mg every 8 weeks (following 450 mg loading dose) for 52 weeks or placebo for 24 weeks.”
> “plans to submit a Biologics License Application (BLA) to the FDA in 2027.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-2.1.2.14-4"></a>

### Barzolvolimab: subcutaneous pre-filled syringe and potential self-administration at home

> “Our barzolvolimab drug product is currently administered subcutaneously.”
> “The subcutaneous formulation allows for potential self-administration at home, eliminating the need for intravenous dosing in a hospital or clinic setting.”
> “Drug product manufacturing into 1 mL pre-filled syringes has been completed and pre-filled syringes are actively being used in Phase 3 trials.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-2.1.2.14-5"></a>

### Barzolvolimab: Week 12 UAS7 change and UAS7=0 in EMBARQ-CSU1 and EMBARQ-CSU2

> “Both Phase 3 trials met the primary endpoint of mean change from baseline in weekly urticaria activity score (UAS7) at Week 12, and all key secondary endpoints”
> “Proportion of Patients with Complete Response (UAS7=0) at Weeks 12 and 24”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

| Arm | EMBARQ-CSU1 LS mean change (SE) in UAS7 at Week 12 | EMBARQ-CSU2 LS mean change (SE) in UAS7 at Week 12 | EMBARQ-CSU1 UAS7=0 at Week 12 | EMBARQ-CSU2 UAS7=0 at Week 12 |
| --- | --- | --- | --- | --- |
| Placebo | “-10.7 (0.65)” | “-11.4 (0.64)” | “9.3%” | “12.6%” |
| Barzolvolimab 150 mg every 4 weeks | “-20.2 (0.64)” | “-20.2 (0.63)” | “42.4%” | “45.7%” |
| Barzolvolimab 300 mg every 8 weeks | “-20.5 (0.65)” | “-19.7 (0.64)” | “42.1%” | “44.0%” |

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-2.1.2.14-6"></a>

### Omalizumab: CSU indication, subcutaneous dosing every 4 weeks, and administration setting

> “Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment (1.4)”
> “The recommended dosage for chronic spontaneous urticaria (CSU) is XOLAIR 150 mg or 300 mg by subcutaneous injection every 4 weeks.”
> “Dosing of XOLAIR in CSU patients is not dependent on serum IgE (free or total) level or body weight.”
> “Initiate therapy in a healthcare setting and once therapy has been safely established, the healthcare provider may determine whether self-administration of XOLAIR prefilled syringe or autoinjector by the patient or caregiver is appropriate, based on careful assessment of risk for anaphylaxis and mitigation strategies.”

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

<a id="topic-2.1.2.14-7"></a>

### Omalizumab: anaphylaxis boxed warning

> “WARNING: ANAPHYLAXIS”
> “Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment.”

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

### Omalizumab: UAS7=0 at Week 12 in CSU Trial 1

> “In CSU Trial 1, a larger proportion of patients treated with XOLAIR 300 mg (36%) reported no itch and no hives (UAS7=0) at Week 12 compared to patients treated with XOLAIR 150 mg (15%), XOLAIR 75 mg (12%), and placebo group (9%). Similar results were observed in CSU Trial 2.”

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

<a id="topic-2.1.2.14-9"></a>

### Omalizumab list price

> “of XOLAIR is approximately $30,000 - $60,000 annually, but most people will not pay this amount.”
> “Current list price refers to the wholesale acquisition cost (WAC).”

Source: [Genentech Xolair cost page (2026)](https://www.xolair.com/cost.html)

<a id="topic-2.1.2.14-10"></a>

### Dupilumab: CSU indication and subcutaneous dosing every 2 weeks in adults

> “DUPIXENT is indicated for the treatment of adult and pediatric patients aged 2 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment.”
> “The recommended dosage of DUPIXENT for adult patients is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every 2 weeks (Q2W).”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.1.2.14-11"></a>

### Dupilumab: CUPID Study A and Study C results at Week 24, and Study B

> “The key secondary endpoint was change from baseline in urticaria activity score over 7 days (UAS7) at Week 24.”
> “The efficacy of DUPIXENT was based only on CUPID Study A and Study C; Study B did not meet the primary endpoint.”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

| Outcome at Week 24 | CUPID Study A dupilumab (N=68) | CUPID Study A placebo (N=68) | CUPID Study C dupilumab (N=73) | CUPID Study C placebo (N=75) |
| --- | --- | --- | --- | --- |
| LS mean change (SE) in UAS7 | “-20.99 (1.77)” | “-11.95 (1.81)” | “-15.61 (2.62)” | “-11.27 (2.61)” |
| UAS7 ≤6, n (%) | “32 (47.1)” | “16 (23.5)” | “29 (39.7)” | “17 (22.7)” |
| UAS7 = 0, n (%) | “22 (32.4)” | “9 (13.2)” | “22 (30.1)” | “13 (17.3)” |

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.1.2.14-12"></a>

### Dupilumab list price

> “$4,193.03 per 4-week supply”
> “A four-week supply of DUPIXENT (200mg or 300 mg) is defined as two injections. Pricing as of January 1, 2026.”

Source: [Regeneron Dupixent Colorado price disclosure (2026)](https://www.regeneron.com/downloads/codrugcosteducation_dupixent.pdf)

<a id="topic-2.1.2.14-13"></a>

### Remibrutinib: CSU indication in adults and oral dosing twice daily

> “RHAPSIDO® is indicated for adult patients who remain symptomatic despite use of H1 antihistamine for the treatment of:”
> “chronic spontaneous urticaria (1)”
> “The recommended dosage is 25 mg taken orally twice daily with or without food.”

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

<a id="topic-2.1.2.14-14"></a>

### Remibrutinib: UAS7 change, UAS7 ≤6, and UAS7 = 0 at Week 12 in REMIX-1 and REMIX-2

> “The key secondary endpoint was absolute change from baseline in UAS7 at Week 12.”
> “Secondary endpoints included proportion of patients who achieved UAS7 ≤6 at Weeks 2 and 12, and the proportion of patients who achieved complete absence of itch and hives (UAS7 = 0) at Week 12.”
> “Multiple imputation techniques were implemented for missing data.”

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

| Outcome at Week 12 | REMIX-1 remibrutinib (N = 309) | REMIX-1 placebo (N = 153) | REMIX-2 remibrutinib (N = 297) | REMIX-2 placebo (N = 153) |
| --- | --- | --- | --- | --- |
| LS mean (SE) change in UAS7 | “-20.02 (0.72)” | “-13.79 (0.98)” | “-19.41 (0.70)” | “-11.73 (0.95)” |
| UAS7 ≤6, n (%) | “154 (49.8)” | “38 (24.8)” | “139 (46.8)” | “30 (19.6)” |
| UAS7 = 0, n (%) | “96 (31.1)” | “16 (10.5)” | “83 (27.9)” | “10 (6.5)” |

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

<a id="topic-2.1.2.14-15"></a>

### Remibrutinib list price

> “The list (or wholesale) price for RHAPSIDO, as of January 7, 2026, is $4,521 per package (30-day supply, 60 tablets).”

Source: [Novartis Rhapsido savings and support page (2026)](https://www.rhapsido.com/savings-support)

<a id="topic-2.1.2.14-16"></a>

### Draft joint task force guideline: direct and retail prices of omalizumab, dupilumab, and remibrutinib as of December 2025

| Medication | Example packages | Direct price | Retail price |
| --- | --- | --- | --- |
| Omalizumab | “1 syringe/pen per box” | “$1475 per month” | “$1,525.61 per 150mg” |
| Dupilumab | “Carton” | “$4,193.03 per carton” | “$3100.84-5132.09 per carton” |
| Remibrutinib | “60 tablets” | “$4,424.01 per bottle” | “$4,521 per bottle” |

Source: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

> “Prices in US dollars from GoodRx, CostPlusDrugs, and manufacturer”
> “websites as of December 2025.”

Source: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

<a id="topic-2.1.2.14-17"></a>

### International guideline: dupilumab effect relative to omalizumab, oral remibrutinib, and cost restrictions

> “Results of Phase 3 studies show the efficacy of dupilumab as add‐on treatment, which is however, likely to be less pronounced than those observed with omalizumab”
> “In September 2025 remibrutinib was approved by the FDA as an oral treatment for adult patients with CSU who remain symptomatic despite H1‐antihistamine treatment and does not require injections or lab monitoring”
> “but it is acknowledged that omalizumab, dupilumab, and remibrutinib have restrictions due to their high cost”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.1.2.14-18"></a>

### Network meta-analysis for the joint task force guideline: omalizumab and remibrutinib among the most effective

> “As part of updating the AAAAI/ACAAI JTFPP chronic urticaria guidelines”
> “We included 93 studies (n = 11,398; mostly adult and adolescent participants across 83 randomized trials and 10 nonrandomized studies) that evaluated 42 interventions.”
> “With high certainty, standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib are among the most effective for improving multiple patient-important outcomes. The safety profile of remibrutinib, however, is less certain. Dupilumab improved urticaria activity, but its impact on quality of life is uncertain, and no dupilumab trials addressed angioedema activity.”

Source: [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004)

<a id="topic-2.1.2.14-19"></a>

### Network meta-analysis of biologic and targeted synthetic treatments for antihistamine-refractory CSU

> “Most biological and synthetic target‐specific drugs for antihistamine‐refractory chronic spontaneous urticaria (CSU) have not been compared head‐to‐head.”
> “23 randomized clinical trials with 6933 participants that compared 26 different interventions or dosages and placebos were included.”
> “Omalizumab 300 mg [MD −10.07, 95% CI (−11.35; −8.82)] continues to demonstrate superior efficacy compared with placebo. Remibrutinib, at doses of 35 mg once daily [MD −7.80, 95% CI (−12.76; −2.51)], 25 mg twice daily [MD −7.69, 95% CI (−9.85; −5.76)], and 10 mg twice daily [MD −7.61, 95% CI (−12.59; −2.47)], had the best overall performance for efficacy and safety. Dupilumab, fenebrutinib, and rilzabrutinib also showed greater efficacy than placebo.”
> “No significant differences were found among all treatment comparisons for AEs and SAEs.”

Source: [Zhao et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12053928/)

<a id="topic-2.1.2.14-20"></a>

### Network meta-analysis of omalizumab, dupilumab, and remibrutinib at Weeks 12 and 24

> “Urticaria Activity Score (UAS7), Itch Severity Score (ISS7), Dermatology Life Quality Index (DLQI; DLQI 0/1), disease control (UAS7 ≤ 6), and symptom remission (UAS7 = 0) were assessed at weeks 12/24.”
> “Fifteen studies (4,913 patients) were included. Omalizumab 300 mg demonstrated the greatest efficacy in UAS7, ISS7, symptom remission, and disease control at both timepoints. Remibrutinib showed the greatest DLQI improvement and second-highest UAS7 reduction and odds of symptom remission. Dupilumab provided sustained itch relief but delayed efficacy. Lower omalizumab doses lacked durability at 24 weeks.”

Source: [Xiong et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41186128/)

<a id="topic-2.1.2.14-21"></a>

### Time to minimal clinically important difference in UAS7 across approved and investigational therapies

> “This study aims to provide indirect evidence on the relative time to meaningful clinical response across approved and investigational therapies using a Bayesian network meta-analysis.”
> “The primary outcome was the mean time in weeks to minimal clinically important difference (MCID), defined as a UAS7 reduction of 10 points.”
> “Only omalizumab 300 mg every 4 weeks, dupilumab 300 mg every 2 weeks, and ligelizumab 72 mg and 120 mg every 4 weeks achieved statistically significant reductions compared with placebo. All treatments had wide credible intervals reflecting limited direct comparisons.”

Source: [Balachandar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13301777/)

<a id="topic-2.1.2.14-22"></a>

### Matching-adjusted indirect comparison of omalizumab versus dupilumab at Week 12

> “Pooled patient-level data from the omalizumab ASTERIA I/II trials ( NCT01287117 /01292473) were compared with published aggregate data from the dupilumab LIBERTY-CSU CUPID Study A trial”
> “Improvements in both disease activity and itch severity were statistically significantly greater for omalizumab versus dupilumab (least squares mean [95% confidence interval] difference: UAS7, −7.6 [−13.0, −2.2], P = .006; ISS7, −3.0 [−5.8, −0.3], P = .031).”
> “Change from baseline in UAS7 at week 12 for omalizumab versus placebo was −12.6 (−15.7, −9.5) and for dupilumab versus placebo was −5.0 (−9.3, −0.7).”

Source: [Mosnaim et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12990347/)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
